Trial Matching
Embedding clinical trial screening into routine clinical care — clinical workflow and AI-driven automation from trial curation to patient matching.
The Vizlitics clinical trial suite automates the entire trial-matching workflow — from protocol ingestion to patient enrollment. The system reads each protocol, breaks it into individual eligibility rules, and evaluates them against the full longitudinal chart — automatically narrowing thousands of chart-trial combinations down to the handful of patients who actually qualify. Every patient is screened against every open trial at your site, with matches and evidence surfaced at the point of care.
Trial curation
Protocol ingestion · eligibility structuring · patient selection
EXPAND: safety & efficacy of the 10 GE Xenokidney in end-stage renal disease.
ESRD · Kidney transplantation · Xenotransplantation · NCT06878560Finerenone on morbidity & mortality in heart failure with LVEF ≥ 40%.
Acute heart failure · Heart failure · NCT06008197Ensifentrine–glycopyrrolate fixed-dose combination in COPD (Phase IIb).
Chronic obstructive pulmonary disease · NCT07016412SPECT-CT guided elective contralateral neck treatment for lateralized oropharyngeal cancer (Phase III).
Oropharyngeal cancer · NCT05451004Nivolumab vs nivolumab + BMS-986016 (relatlimab) as maintenance after 1L platinum-gemcitabine.
Metastatic / recurrent nasopharyngeal carcinoma · NCT06029270EXPAND · GPK-KF-101
Inclusion criteria · auto-classified
Patient selection metrics
Study ID NCT06029270
Age — min 18, max — · Gender — All
Metastatic nasopharyngeal carcinoma · C11.0, C11.1, C11.2, C11.3, C11.8, C11.9
Recurrent nasopharyngeal carcinoma · C11.0–C11.9
Trial graph
Disease → subtype → setting → matched trials
Official title: Evaluation of talazoparib, a PARP inhibitor, in patients with somatic BRCA-mutant metastatic breast cancer — genotyping-based clinical trial.
Official title: Randomized, open-label study of the Bria-IMT regimen and checkpoint inhibitor vs physician’s choice in advanced metastatic breast cancer (BRIA-ABC).
Eligibility screening · CCTG-HN11
Prescreening · NCT05451004
Evidence
Evidence summary. The tumor is consistently reported as HPV-positive across the record:
- p16 IHC positive and high-risk HPV E6/E7 mRNA detected at baseline, with repeated confirmation through +20 mo, plus a positive HPV DNA assay.
- Addendum to the +16 mo surgical pathology report: p16 IHC positive in tumor cells.
- No documentation of an HPV-negative result in any note.
Conclusion. The criterion is satisfied — evidence unequivocally shows HPV positivity.
CRITERIA_MET · Status: YesEvidence
Ipsilateral lymph nodes ≤6 cm.
- CT chest (+31 mo): enlarged right hilar node 12 mm.
- CT neck (+15 mo): right level 2A nodes, largest 10 mm.
- Surgical pathology (+16 mo): metastatic SCC in a 1.8 cm right level 2A node.
- PET/CT (+3 wks): right cervical nodal conglomerate 5.5 × 3.9 cm.
Clinical stage T1–3 M0. 3.5 cm exophytic right-oropharynx mass (baseline) meets T1–3; HPV-positive non-keratinizing SCC, T3 N1 M0. Post-CRT and right-neck dissection (+16 mo): complete resolution; subsequent PET/CT (+22 mo) no suspicious uptake; no distant metastasis.
CRITERIA_MET · Status: YesOnTrial — performance metrics
Clinical trial matching dashboard · last week
Pre-screening by day
Distribution by age
Screening volume
| Visit type | 06/23 | 06/24 | 06/29 | Total |
|---|---|---|---|---|
| Established | 7 | 0 | 2 | 9 |
| New | 3 | 9 | 1 | 13 |
| New in CI | 4 | 0 | 3 | 8 |
| Patient totals | 14 | 9 | 6 | 30 |
Distribution by race
Trial details · count 26
DRUG TOS-358-001 · BreastPhase I
DRUG STML-ELA-0422 · BreastPhase III
NRG HN011 · Head & NeckPhase II
Alliance A092105 · Head & NeckPhase II
The AI inside Trial Matching
AI that reasons over eligibility — one criterion at a time.
Trial Matching extracts inclusion and exclusion criteria from each protocol and translates them into clinical concepts the system can screen against the structured record — criterion by criterion. Matching is explainable and continuous: every pass or fail carries its evidence, and screening re-runs automatically as the data changes.
Evidence-first: patient selection is only as good as the evidence surfaced from the medical record. The innovation is the depth and breadth of reasoning across the complete record — with conclusive determinations at both the trial and criterion level.
What it costs
Screening shouldn't depend on who a coordinator already knows.
Eligible patients are missed
Screening only reaches the patients a coordinator already knew to check; everyone else falls through.
Skilled staff burned on busywork
Trial nurses and coordinators spend hours on ad-hoc requests and manual review instead of patient-facing work.
Enrollment stays low
Fewer trials surfaced at the point of care means fewer patients ever enrolled.
The problem today
Trials are offered too late, if at all.
No visibility
Providers can't see which trials are open while the patient is still in the room.
Too slow to scale
Manual chart-by-chart, trial-by-trial review runs ~45 min per patient and is easy to get wrong.
Too late
Matching happens after the visit ends, once the window to offer a trial has already closed.
OnTrial · 5 integrated modules
EHR-integrated workflow for end-to trial automation.
Trial Curation
Automated extraction
Protocols are structured and AI-ready before screening begins — ClinicalTrials.gov & CTMS ingestion, hierarchical I/E criteria parsing, and ICD-code mapping.
Pre-Screening
High-volume matching
Every patient is matched to eligible trials before they walk in — appointment-triggered 3–5 days ahead, ICD-based trial matching, with Match / No Match / Unknown outcomes.
Trial-Centric
Batch screening with RWD
Rapidly identify eligible patients from your existing population when a new trial launches — screen 6–12 months of patients, RWD-powered cohort queries, 50+ screened on day one of activation.
Full Screening
Enrollment evaluation
AI evaluates every criterion with cited evidence for coordinator review — each I/E criterion evaluated, source documents linked, AI reasoning with clinical conclusions.
Performance
Analytics & reporting
Measure and optimize enrollment across trials and disease areas — enrollment-lifecycle tracking, accept/reject rates, and cross-trial benchmarking.
Deployment workflows
Three ways to run it — patient-first, trial-first, and on-demand.
Eligibility, checked at the criterion — and re-checked every day.
Trial Matching breaks each protocol into individual eligibility criteria and screens every patient against them from the curated record. As new pathology, imaging, or molecular results arrive, patients are automatically re-screened — surfacing eligible candidates the moment they qualify. The same criterion-level engine also matches trials for nephrology, hepatology, pulmonology, and cardiology.
Criteria-level eligibility
Every inclusion and exclusion checked individually, with the evidence behind each call.
- Diagnosis, stage, prior lines, and ECOG
- Per-criterion pass/fail with source links
- No black-box match scores
Continuous re-screening
The record changes; eligibility recomputes — no waiting for a manual review cycle.
- Re-screen triggered by new results
- Newly eligible patients flagged automatically
- Screening history retained for audit
Biomarker-aware matching
Molecular eligibility handled with the same structured biomarker layer used across the platform.
- Gene · variant · result matching
- PD-L1, MSI/MMR and companion criteria
- mCODE-aligned representation
CRC worklist & audit trail
A ranked worklist that changes the research coordinator's day from searching to reviewing.
- Prioritized candidate queue
- Full per-patient audit trail
- SMART on FHIR launch in the EHR
Standards & frameworks
Bring Trial Matching to your service line.
We start from complete records — retrieval and curation first, then Trial Matching on top.
